Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 439

1.

Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.

Star P, Goodwin A, Kapoor R, Conway RM, Long GV, Scolyer RA, Guitera P.

Eur J Cancer. 2018 Feb 2;92:48-53. doi: 10.1016/j.ejca.2017.12.022. [Epub ahead of print]

PMID:
29413689
2.

Impact of genomics on the surgical management of melanoma.

Ferguson PM, Long GV, Scolyer RA, Thompson JF.

Br J Surg. 2018 Jan;105(2):e31-e47. doi: 10.1002/bjs.10751. Review.

PMID:
29341162
3.

Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors.

Lo SN, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2018 Jan 12. doi: 10.1245/s10434-017-6325-1. [Epub ahead of print]

PMID:
29330716
4.

RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkahloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, Brodezki A, Rosenberg SA, Kosloff M, Hayward NK, Admon A, Niv MY, Scolyer RA, Martemyanov KA, Samuels Y.

Sci Rep. 2018 Jan 12;8(1):653. doi: 10.1038/s41598-017-18851-4.

5.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

PMID:
29320474
6.

Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging.

Dodds TJ, Lo S, Jackett L, Nieweg O, Thompson JF, Scolyer RA.

Am J Surg Pathol. 2018 Mar;42(3):359-366. doi: 10.1097/PAS.0000000000000999.

PMID:
29240580
7.

A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma.

Sykes EK, McDonald CE, Ghazanfar S, Mactier S, Thompson JF, Scolyer RA, Yang JY, Mann GJ, Christopherson RI.

Proteomics Clin Appl. 2017 Dec 11. doi: 10.1002/prca.201700094. [Epub ahead of print]

PMID:
29227041
8.

Conditional survival estimates for cancer patients.

Haydu LE, Scolyer RA, Thompson JF.

Oncotarget. 2017 Oct 4;8(49):84639-84640. doi: 10.18632/oncotarget.21497. eCollection 2017 Oct 17. No abstract available.

9.

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.

Lim SY, Lee JH, Welsh SJ, Ahn SB, Breen E, Khan A, Carlino MS, Menzies AM, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 Nov 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017.

10.

Trajectories of premalignancy during the journey from melanocyte to melanoma.

Colebatch AJ, Scolyer RA.

Pathology. 2018 Jan;50(1):16-23. doi: 10.1016/j.pathol.2017.09.002. Epub 2017 Nov 10. Review.

PMID:
29132722
11.

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Gide TN, Wilmott JS, Scolyer RA, Long GV.

Clin Cancer Res. 2017 Nov 10. doi: 10.1158/1078-0432.CCR-17-2267. [Epub ahead of print] Review.

PMID:
29127120
12.

The Importance of Population-Based Estimates of Melanocytic Pathology.

Bell KJL, Cust AE, Scolyer RA.

JAMA Dermatol. 2018 Jan 1;154(1):15-17. doi: 10.1001/jamadermatol.2017.4061. No abstract available.

PMID:
29094157
13.

Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.

Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):660. doi: 10.1245/s10434-017-6170-2. Epub 2017 Oct 27. No abstract available.

PMID:
29079922
14.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

PMID:
29045907
15.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

16.

Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress.

Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, Yan XG, Thorne RF, Scolyer RA, Zhang XD, Jin L.

Cancer Res. 2017 Nov 15;77(22):6226-6239. doi: 10.1158/0008-5472.CAN-17-1965. Epub 2017 Sep 25.

PMID:
28947420
17.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

18.

Punch 'scoring': a technique that facilitates melanoma diagnosis of clinically suspicious pigmented lesions.

Grogan J, Cooper CL, Dodds TJ, Guitera P, Menzies SW, Scolyer RA.

Histopathology. 2018 Jan;72(2):294-304. doi: 10.1111/his.13342. Epub 2017 Oct 17.

PMID:
28796900
19.

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Mod Pathol. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4.

PMID:
28776578
20.

Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.

Varey AHR, Goumas C, Hong AM, Mann GJ, Fogarty GB, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Lee KJ, Quinn MJ, Thompson JF, Scolyer RA.

Mod Pathol. 2017 Nov;30(11):1538-1550. doi: 10.1038/modpathol.2017.76. Epub 2017 Jul 21.

PMID:
28731051
21.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

PMID:
28724663
22.

Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma.

Rawson RV, Watson GF, Maher AM, McCarthy SW, Thompson JF, Scolyer RA.

Pathology. 2017 Aug;49(5):539-542. doi: 10.1016/j.pathol.2017.03.005. Epub 2017 Jul 8. No abstract available.

PMID:
28693747
23.

Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas.

Rawson RV, Robbins E, Kapoor R, Scolyer RA, Long GV.

Eur J Cancer. 2017 Sep;82:167-170. doi: 10.1016/j.ejca.2017.05.042. Epub 2017 Jul 6. No abstract available.

PMID:
28689094
24.

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.

Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M.

Cancer Res. 2017 Sep 1;77(17):4697-4709. doi: 10.1158/0008-5472.CAN-17-0395. Epub 2017 Jun 26.

PMID:
28652246
25.

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ.

Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26.

PMID:
28652244
26.

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.

J Thorac Oncol. 2017 Sep;12(9):1421-1433. doi: 10.1016/j.jtho.2017.05.024. Epub 2017 Jun 16.

PMID:
28629895
27.

Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy.

Maher NG, Solinas A, Scolyer RA, Puig S, Pellacani G, Guitera P.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):2016-2024. doi: 10.1111/jdv.14381. Epub 2017 Jul 3.

PMID:
28573666
28.

Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia.

Varey AHR, Madronio CM, Cust AE, Goumas C, Mann GJ, Armstrong BK, Scolyer RA, Curtin AM, Thompson JF.

Ann Surg Oncol. 2017 Aug;24(8):2080-2088. doi: 10.1245/s10434-017-5890-7. Epub 2017 May 25.

PMID:
28547563
29.

Computer-assisted diagnosis for skin cancer: have we been outsmarted?

Mar VJ, Scolyer RA, Long GV.

Lancet. 2017 May 20;389(10083):1962-1964. doi: 10.1016/S0140-6736(17)31285-0. No abstract available.

PMID:
28534744
30.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.

PMID:
28512174
31.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017.

32.

Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors.

van de Nes JAP, Koelsche C, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Pietsch T, Murali R, Schadendorf D, Griewank KG.

J Invest Dermatol. 2017 Sep;137(9):2033-2035. doi: 10.1016/j.jid.2017.04.022. Epub 2017 May 10. No abstract available.

PMID:
28499758
33.

The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

Wilmott JS, Rizos H, Scolyer RA, Long GV.

Clin Cancer Res. 2017 Jun 15;23(12):2921-2923. doi: 10.1158/1078-0432.CCR-17-0669. Epub 2017 May 3.

PMID:
28468948
34.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
35.

In Vivo Reflectance Confocal Microscopy for the Diagnosis of Melanoma and Melanotic Macules of the Lip.

Uribe P, Collgros H, Scolyer RA, Menzies SW, Guitera P.

JAMA Dermatol. 2017 Sep 1;153(9):882-891. doi: 10.1001/jamadermatol.2017.0504.

PMID:
28467525
36.

SF3B1 and BAP1 mutations in blue nevus-like melanoma.

Griewank KG, Müller H, Jackett LA, Emberger M, Möller I, van de Nes JA, Zimmer L, Livingstone E, Wiesner T, Scholz SL, Cosgarea I, Sucker A, Schimming T, Hillen U, Schilling B, Paschen A, Reis H, Mentzel T, Kutzner H, Rütten A, Murali R, Scolyer RA, Schadendorf D.

Mod Pathol. 2017 Jul;30(7):928-939. doi: 10.1038/modpathol.2017.23. Epub 2017 Apr 14.

PMID:
28409567
37.

Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.

Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, Stretch JR, McCarthy WH, Thompson JF.

J Clin Oncol. 2017 May 20;35(15):1721-1729. doi: 10.1200/JCO.2016.71.9393. Epub 2017 Apr 4.

PMID:
28375785
38.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.

PMID:
28327969
39.

Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients.

Crookes TR, Scolyer RA, Lo S, Drummond M, Spillane AJ.

Ann Surg Oncol. 2017 May;24(5):1378-1385. doi: 10.1245/s10434-016-5723-0. Epub 2017 Jan 27.

PMID:
28130620
40.

Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Rawson RV, Johansson PA, Hayward NK, Waddell N, Patch AM, Lo S, Pearson JV, Thompson JF, Mann GJ, Scolyer RA, Wilmott JS.

Lab Invest. 2017 Feb;97(2):130-145. doi: 10.1038/labinvest.2016.143. Epub 2017 Jan 9.

41.

5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.

Lee JJ, Vilain RE, Granter SR, Hu NR, Bresler SC, Xu S, Frank AH, Mihm MC Jr, Saw RP, Fletcher CD, Scolyer RA, Murphy GF, Lian CG.

J Cutan Pathol. 2017 Mar;44(3):249-255. doi: 10.1111/cup.12880. Epub 2017 Feb 6.

PMID:
28032662
42.

Mutation load in melanoma is affected by MC1R genotype.

Johansson PA, Pritchard AL, Patch AM, Wilmott JS, Pearson JV, Waddell N, Scolyer RA, Mann GJ, Hayward NK.

Pigment Cell Melanoma Res. 2017 Mar;30(2):255-258. doi: 10.1111/pcmr.12571. Epub 2017 Mar 7.

PMID:
28024115
43.

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A.

Sci Transl Med. 2016 Dec 14;8(369):369ra177.

PMID:
27974665
44.

Lethal melanoma in children: a clinicopathological study of 12 cases.

Prieto-Granada CN, Lezcano C, Scolyer RA, Mihm MC Jr, Piris A.

Pathology. 2016 Dec;48(7):705-711. doi: 10.1016/j.pathol.2016.08.008. Epub 2016 Oct 27.

PMID:
27956274
45.

Resistance to PD1/PDL1 checkpoint inhibition.

O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ.

Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27. Review.

PMID:
27951441
46.

Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.

Möller I, Murali R, Müller H, Wiesner T, Jackett LA, Scholz SL, Cosgarea I, van de Nes JA, Sucker A, Hillen U, Schilling B, Paschen A, Kutzner H, Rütten A, Böckers M, Scolyer RA, Schadendorf D, Griewank KG.

Mod Pathol. 2017 Mar;30(3):350-356. doi: 10.1038/modpathol.2016.201. Epub 2016 Dec 9.

PMID:
27934878
47.

Authors' response to a reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'.

Damian DL, Martin AJ, Scolyer RA, Chen AC, Halliday GM.

Br J Dermatol. 2017 Feb;176(2):552-553. doi: 10.1111/bjd.15204. Epub 2017 Jan 25. No abstract available.

PMID:
27893156
48.

Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions.

Maher NG, Blumetti TP, Gomes EE, Cheng HM, Satgunaseelan L, Lo S, Rezze GG, Scolyer RA, Guitera P.

Br J Dermatol. 2017 Aug;177(2):574-577. doi: 10.1111/bjd.15187. Epub 2017 Jun 22. No abstract available.

PMID:
27861726
49.

A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types.

Patrick E, Schramm SJ, Ormerod JT, Scolyer RA, Mann GJ, Mueller S, Yang JY.

Oncotarget. 2017 Jan 10;8(2):2807-2815. doi: 10.18632/oncotarget.13203.

50.

A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.

Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, Scolyer RA, Dhillon HM, Vardy JL, Bielski VA, Halliday GM, Damian DL.

Br J Dermatol. 2016 Nov;175(5):1073-1075. doi: 10.1111/bjd.14662. Epub 2016 Aug 10. No abstract available.

PMID:
27061568

Supplemental Content

Loading ...
Support Center